The addressable market for Agenus in terms of royalties payable to Agenus is $100 million for non-small cell lung cancer and for melanoma it is $31 million. Though viral glycoproteins are thought to function during viral entry via the classic pathway irrespective of pH, the endocytic pathway has been found to be pH dependent in certain cell types [41,42]. This apparent contradiction invites an important question: Can an HSV-1 vaccine be implemented universally for prophylactic and therapeutic use to limit HSV-1 pathogenicity? Science. Prevnar is the top-selling vaccine in the world, and used primarily in children. We do not anticipate further developing AG-702, given that AG-707 has a potential to benefit a larger number of patients with genital herpes. Based on the results of completed toxicology studies and other preclinical activities, we submitted to the FDA an IND for AG-707 during the second quarter of 2005.

Comparing the trial participants’ UL5 sequences from all available samples to the consensus, we identified 8 sites with nonsynonymous mutations, all involving a single nucleotide difference (Supplementary Table 9). 18. Infect. This HERPES will be securely recorded for verification purposes. The reaction mixture was diluted with saturated NaHC03 and extracted with EA. At month 4, response rates were similar for the 3 vaccine groups (72.4%-76.9%). The inhibitory activity against herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) was tested in vitro on RC-37 cells using a plaque reduction assay.

Maybe a little bit more challenging, but not over. Herpesvirus 1 (alpha), Equine A species of VARICELLOVIRUS causing abortion and respiratory disease in horses. PMC 120683. Recently, our research group, for first time, applied Leishmania tarentolae, as a recombinant HPV vaccine candidate to improve the efficacy of HPV vaccine strategies. Currently, these are being largely ignored by biotechnology investors. QS-21 Stimulon adjuvant and the related agreements, and HerpV are assets of Antigenics Inc., a wholly owned subsidiary of Agenus Inc. For more information, please visit

Despite multiple approaches to therapy and prevention, HSV-1 and HSV-2 remain among the most common infectious agents of humans 7, 9, 10. is a biotechnology company working to develop treatments for cancers and infectious diseases. Now, it’s built on That lead with New Phase II results for ITS therapeutic candidate, HerpV, Which Achieved statistical significance in viral load Reducing. Agenus Inc, a therapeutic vaccine maker based in Lexington, said it has positive results from a Phase 1 study of its HerpV vaccine for genital herpes, and plans to move it into a Phase 2 study in 2012. The 14 kDa homodimeric N1L protein is a potent vaccinia and variola (smallpox) virulence factor. The initial data support that vaccination with HerpV has a real, measurable biological effect lowering the active shedding of the virus. Centers for Disease Control and Prevention estimated in surveys from 1997 that about one in five people in the United States ages 12 or older is infected with HSV-2.

During the spring surveys, AGFD encountered far more channel catfish than usual, the majority in the 2-6 lb range, and they were in very good condition. Findings from a preliminary analysis have been reported.23 The present analysis represents an updated report after the final accrual goal was achieved and with a median follow-up of censored patients of 45 months, which allows the evaluation of long-term efficacy with prognostic factors analysis, including an adequate intention-to-treat analysis. i belieive that the iodine and Prunella Vulgaris is the most effective to fight the herpes viurs. In a four-arm, Phase 1 study, 35 HSV-2 seropositive patients received HerpV (designated in the study as AG-707 plus QS-21), AG-707, QS-21 alone, or placebo. Ill-appearing children are more likely to have serious bacterial infections than well-appearing children; conversely, most well-appearing children do not have serious bacterial infection. The Agenus HerpV vaccine in a Phase II trial (multiple sites) : . In June 2015, at the American Society of Clinical Oncology (ASCO) meeting, we reported positive results from a Phase 2 clinical trial with our Prophage vaccine, which showed that patients with newly-diagnosed GBM who were treated with a combination of our Prophage vaccine and standard of care showed substantial improvement both in progression-free survival and median overall survival, as compared to historical control data.

I’ll briefly review did status of each of the HSV (herpes simplex vaccine contenders), from least to most advanced. Over 400 million people have the herpes simplex sexually transmitted disease. Herpes, or herpes simplex, is a viral disease. Expression of PD-L1 has been shown to be elevated in patients with GBM, and each patient was also evaluated for PD-L1 expression as a predictor of survival. Merck on its part took over the responsibility of further developing and commercializing the candidates under the collaboration. The most common reported adverse event was pain at injection site, fatigue and myalgia.